{"name":"Caribou Biosciences, Inc.","slug":"caribou-biosciences","ticker":"CRBU","exchange":"NASDAQ","domain":"cariboubio.com","description":"Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.","hq":"Berkeley, CA","founded":0,"employees":"97","ceo":"","sector":"Biotech — Cell & Gene Therapy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":2.27,"stockChange":0.15,"stockChangePercent":7.08,"marketCap":"$225M","metrics":{"revenue":11203000,"revenueGrowth":1.9,"grossMargin":0,"rdSpend":0,"netIncome":-133219000,"cash":117626000,"dividendYield":0,"peRatio":-1.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Caribou-sponsored investigational therapy","genericName":"Caribou-sponsored investigational therapy","slug":"caribou-sponsored-investigational-therapy","indication":"Treatment of sickle cell disease","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CB-011","genericName":"CB-011","slug":"cb-011","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Caribou-sponsored investigational therapy","genericName":"Caribou-sponsored investigational therapy","slug":"caribou-sponsored-investigational-therapy","phase":"phase_2","mechanism":"This investigational therapy targets the CRISPR-Cas12 system to modulate gene expression.","indications":["Treatment of sickle cell disease"],"catalyst":""},{"name":"CB-011","genericName":"CB-011","slug":"cb-011","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":11159000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":11159000},{"period":"2024-12-31","value":9994000},{"period":"2023-12-31","value":34477000},{"period":"2022-12-31","value":13851000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":109439000,"rdSpendHistory":[{"period":"2025-12-31","value":109439000},{"period":"2024-12-31","value":130153000},{"period":"2023-12-31","value":112075000},{"period":"2022-12-31","value":82230000}],"sgaSpend":37914000,"operatingIncome":-136194000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-136194000},{"period":"2024-12-31","value":-166616000},{"period":"2023-12-31","value":-116059000},{"period":"2022-12-31","value":-106399000}],"netIncome":-148125000,"netIncomeHistory":[{"period":"2025-12-31","value":-148125000},{"period":"2024-12-31","value":-149105000},{"period":"2023-12-31","value":-102070000},{"period":"2022-12-31","value":-99421000}],"eps":-1.59,"epsHistory":[{"period":"2025-12-31","value":-1.59},{"period":"2024-12-31","value":-1.65},{"period":"2023-12-31","value":-1.38},{"period":"2022-12-31","value":-1.64}],"cash":12360000,"cashHistory":[{"period":"2025-12-31","value":12360000},{"period":"2024-12-31","value":16293000},{"period":"2023-12-31","value":51162000},{"period":"2022-12-31","value":58338000}],"totalAssets":175367000,"totalLiabilities":53192000,"totalDebt":27227000,"equity":122175000,"operatingCashflow":-110992000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-110992000},{"period":"2024-12-31","value":-138200000},{"period":"2023-12-31","value":-93291000},{"period":"2022-12-31","value":-90966000}],"capex":-1359000,"capexHistory":[{"period":"2025-12-31","value":-1359000},{"period":"2024-12-31","value":-6505000},{"period":"2023-12-31","value":-11613000},{"period":"2022-12-31","value":-7054000}],"freeCashflow":-112351000,"dividendsPaid":null,"buybacks":null,"employees":97,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8579000,"ebit":-28453000,"ebitda":-27771000,"period":"2025-12-31","revenue":3941000,"epsBasic":-0.28,"netIncome":-26488000,"rdExpense":23815000,"epsDiluted":-0.28,"grossProfit":null,"operatingIncome":-28453000},{"sga":9197000,"ebit":-29400000,"ebitda":-28769000,"period":"2025-09-30","revenue":2198000,"epsBasic":-0.3,"netIncome":-27548000,"rdExpense":22401000,"epsDiluted":-0.3,"grossProfit":null,"operatingIncome":-29400000},{"sga":10403000,"ebit":-35428000,"ebitda":-34261000,"period":"2025-06-30","revenue":2667000,"epsBasic":-0.58,"netIncome":-54098000,"rdExpense":27692000,"epsDiluted":-0.58,"grossProfit":null,"operatingIncome":-35428000},{"sga":9735000,"ebit":-42913000,"ebitda":-41748000,"period":"2025-03-31","revenue":2353000,"epsBasic":-0.43,"netIncome":-39991000,"rdExpense":35531000,"epsDiluted":-0.43,"grossProfit":null,"operatingIncome":-42913000},{"sga":10488000,"ebit":-38875000,"ebitda":-37691000,"period":"2024-12-31","revenue":2077000,"epsBasic":-0.39,"netIncome":-35490000,"rdExpense":30464000,"epsDiluted":-0.39,"grossProfit":null,"operatingIncome":-38875000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.27,"previousClose":2.12,"fiftyTwoWeekHigh":3.54,"fiftyTwoWeekLow":0.77,"fiftyTwoWeekRange":"0.769 - 3.535","fiftyDayAverage":1.97,"twoHundredDayAverage":1.93,"beta":0,"enterpriseValue":119582816,"forwardPE":-1.6,"priceToBook":2.16,"priceToSales":20.1,"enterpriseToRevenue":10.67,"enterpriseToEbitda":-1.05,"pegRatio":0,"ebitda":-114156000,"ebitdaMargin":0,"freeCashflow":-61984124,"operatingCashflow":-101251000,"totalDebt":26946000,"debtToEquity":26.4,"currentRatio":6.22,"returnOnAssets":-34.7,"returnOnEquity":-83.5,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":12,"targetHighPrice":32,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":8.9,"institutionHeldPercent":38.1,"sharesOutstanding":99180575,"floatShares":94770015,"sharesShort":7123813,"shortRatio":4.9,"shortPercentOfFloat":7.2,"epsTrailing":-1.42,"epsForward":-1.41,"revenuePerShare":0.12,"bookValue":1.05,"officers":[{"age":39,"name":"Dr. Rachel E. Haurwitz Ph.D.","title":"Co-Founder, CEO, President & Director"},{"age":43,"name":"Mr. Sriram  Ryali M.B.A.","title":"Chief Financial Officer"},{"age":70,"name":"Ms. Barbara G. McClung Esq., J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":61,"name":"Dr. Jennifer A. Doudna Ph.D.","title":"Co-founder & Member of Scientific Advisory Board"},{"age":null,"name":"Mr. Ryan  Fischesser","title":"Interim Principal Accounting Officer & Controller"},{"age":55,"name":"Mr. Timothy P. Kelly M.B.A.","title":"Chief Technology Officer"},{"age":null,"name":"Ms. Reigin  Zawadzki","title":"Chief People Officer"},{"age":49,"name":"Ms. Ruhi A. Khan M.B.A.","title":"Chief Business Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://cariboubio.com","phone":"510 982 6030"}}